Cardiopulmonary effects and safety of prostaglandin E1: A review
| Autor: | Hans Klaus Breddin, Gottfried Rudofsky, Heinz Heidrich, Peter Scheffler |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Ejection fraction business.industry Cardiac index Stroke volume Analysis of clinical trials chemistry.chemical_compound chemistry Peripheral arterial occlusive disease Anesthesia Internal medicine Cardiology Medicine Cardiology and Cardiovascular Medicine business Prostaglandin E1 Adverse effect Angiology |
| Zdroj: | International Journal of Angiology. 3:160-168 |
| ISSN: | 1615-5939 1061-1711 |
| DOI: | 10.1007/bf02014937 |
| Popis: | Intraarterial and intravenous infusion of prostaglandin E1 (PGE1) is established treatment for severe peripheral arterial occlusive disease, particularly in Europe and Japan. In this critical appraisal, experimental and clinical studies are reviewed, with special emphasis on cardiopulmonary effects and drug safety. The pulmonary data all indicate dose-dependent dilation of the pulmonary vessels with a reduction in pulmonary resistance. The known hemodynamic effects of PGE1 on the heart include an increase in stroke volume, cardiac index, and left ventricular ejection fraction, and a reduction in left ventricular filling pressure. Analysis of clinical trials shows a low rate of adverse effects, in particular a low incidence of cardiopulmonary side effects. If the recommendations for high-risk patients are observed, PGE1 is both an efficacious and safe therapeutic principle. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|